Package Leaflet: Information for the PatientCoAprovel 300mg/12.5mg film-coated tablets
Irbesartan/Hydrochlorothiazide
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
CoAprovel is a combination of two active substances, irbesartan and hydrochlorothiazide.
Irbesartan belongs to a group of medicines known as angiotensin-II receptor antagonists.
Angiotensin-II is a substance produced in the body that binds to receptors in blood vessels, causing them to constrict. This results in an increase in blood pressure. Irbesartan blocks the binding of angiotensin-II to these receptors, relaxing blood vessels and reducing blood pressure.
Hydrochlorothiazide belongs to a group of medicines called thiazide diuretics, which increase the amount of urine removed from the body, reducing blood pressure.
The two active substances in CoAprovel work together to achieve a greater reduction in blood pressure than either substance alone.
CoAprovel is used to treat high blood pressure, when treatment with irbesartan or hydrochlorothiazide alone does not provide adequate control of blood pressure.
Do not take CoAprovel
Warnings and precautions
Consult your doctor before starting to take CoAprovel and in any of the following cases:
Your doctor may monitor your kidney function, blood pressure, and blood electrolyte levels (e.g., potassium) at regular intervals.
Consult your doctor if you experience abdominal pain, nausea, vomiting, or diarrhea after taking CoAprovel. Your doctor will decide whether to continue treatment. Do not stop taking CoAprovel on your own.
See also the information under the heading “Do not take CoAprovel”.
If you are pregnant, think you may be pregnant, or are planning to become pregnant, inform your doctor. CoAprovel is not recommended during the first trimester of pregnancy and must not be taken after the third month of pregnancy, as it may cause serious harm to your baby (see section “Pregnancy”).
You must also inform your doctor:
Hydrochlorothiazide contained in this medication may cause positive results in doping tests.
Children and adolescents
CoAprovel must not be given to children and adolescents (under 18 years of age).
Using CoAprovel with other medicines
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines.
Diuretics, such as hydrochlorothiazide contained in CoAprovel, may interact with other medicines. You must not take preparations containing lithium with CoAprovel without your doctor's supervision.
Your doctor may need to adjust your dose and/or take other precautions:
If you are taking an angiotensin-converting enzyme inhibitor (ACE inhibitor) or aliskiren (see also the information under the headings “Do not take CoAprovel” and “Warnings and precautions”).
You may need to have blood tests if you take:
It is also important to inform your doctor if you are taking other blood pressure-lowering medicines, steroids, cancer treatments, painkillers, arthritis medicines, or cholesterol-lowering resins such as cholestyramine or colestipol.
Taking CoAprovel with food, drinks, and alcohol
CoAprovel can be taken with or without food.
Due to the hydrochlorothiazide contained in CoAprovel, if you drink alcohol while being treated with this medication, you may experience increased dizziness when standing up, especially when getting up from a seated or lying position.
Pregnancy, breastfeeding, and fertility
Pregnancy
You should inform your doctor if you are pregnant, think you might be pregnant, or are planning to become pregnant. Your doctor will normally advise you to stop taking CoAprovel before you become pregnant or as soon as you know you are pregnant and will recommend that you take a different blood pressure-lowering medicine instead. CoAprovel is not recommended during the first trimester of pregnancy and must not be taken after the third month of pregnancy, as it may cause serious harm to your baby.
Breastfeeding
Inform your doctor if you are about to start or are breastfeeding, as CoAprovel is not recommended for use during breastfeeding. Your doctor may decide to give you a different treatment that is more suitable if you want to breastfeed, especially if you are breastfeeding newborns or premature babies.
Driving and using machines
CoAprovel is unlikely to affect your ability to drive or use machines. However, during treatment for high blood pressure, dizziness or fatigue may occasionally occur. If you experience these symptoms, talk to your doctor before driving or using machines.
CoAprovel contains lactose. If your doctor has told you that you have an intolerance to some sugars, contact them before taking this medicine.
CoAprovel contains sodium. This medicine contains less than 1 mmol of sodium (23 mg) per tablet, which is essentially “sodium-free”.
Always take this medicine exactly as your doctor has told you. If you are not sure, check with your doctor or pharmacist.
Dose
The recommended dose of CoAprovel is one tablet per day. In general, your doctor will prescribe CoAprovel when previous treatments you received did not sufficiently reduce your blood pressure. Your doctor will indicate how to switch from previous treatments to CoAprovel.
Method of administration
CoAprovel is taken orally. The tablets should be swallowed with a sufficient amount of liquid (e.g., a glass of water). You can take CoAprovel with or without food. Try to take your daily dose at the same time each day. It is important that you continue to take CoAprovel until your doctor tells you to stop.
The maximum blood pressure-lowering effect should be achieved within 6-8 weeks after starting treatment.
If you take more CoAprovel than you should
If you accidentally take too many tablets, contact your doctor immediately.
Children must not take CoAprovel
CoAprovel must not be given to children under 18 years of age. If a child swallows some tablets, contact your doctor immediately.
If you forget to take CoAprovel
If you accidentally miss a dose, simply take your normal dose when it is due next. Do not take a double dose to make up for forgotten doses.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, CoAprovel can cause side effects, although not everybody gets them.
Some of these effects can be serious and may require medical attention.
Rarely, cases of allergic skin reactions (skin rash, urticaria) have been reported in patients treated with irbesartan, as well as localized swelling in the face, lips, and/or tongue. If you have any of the above symptoms or experience shortness of breath, stop taking CoAprovel and contact your doctor immediately.
The frequency of side effects is defined using the following convention:
Common: may affect up to 1 in 10 people
Uncommon: may affect up to 1 in 100 people
The side effects reported in clinical studies for patients treated with CoAprovel were:
Common side effects(may affect up to 1 in 10 people):
If any of these side effects bother you, talk to your doctor
Uncommon side effects(may affect up to 1 in 100 people):
If any of these side effects bother you, talk to your doctor
Side effects reported since CoAprovel has been marketed
Since CoAprovel has been marketed, some side effects have been reported. The frequency of these side effects is not known: headache, ringing in the ears, cough, altered taste, indigestion, muscle and joint pain, liver function disorders, kidney failure, high potassium levels in the blood, and allergic reactions such as skin rash, urticaria, swelling of the face, lips, mouth, tongue, or throat. Rare cases of jaundice (yellowing of the skin and/or whites of the eyes) have also been observed.
As with all combinations of two active substances, it cannot be excluded that side effects associated with each of the components may occur.
Side effects associated only with irbesartan
In addition to the side effects described above, the following have also been reported: chest pain, severe allergic reactions (anaphylactic shock), decreased red blood cell count (anemia - symptoms may include fatigue, headaches, difficulty breathing when exercising, dizziness, and paleness), and decreased platelet count, as well as low blood sugar levels.
Rare (may affect up to 1 in 1,000 people): intestinal angioedema: swelling in the intestine that presents with symptoms such as abdominal pain, nausea, vomiting, and diarrhea.
Side effects associated with hydrochlorothiazide in monotherapy
Loss of appetite; stomach upset; stomach cramps; constipation; jaundice (yellowing of the skin and/or whites of the eyes); pancreatitis characterized by severe upper abdominal pain, often with nausea and vomiting; sleep disorders; depression; blurred vision; low white blood cell count, which can lead to frequent infections, fever; decreased platelet count (a blood cell essential for blood clotting), decreased red blood cell count (anemia) characterized by fatigue, headaches, shortness of breath when exercising, dizziness, and paleness; kidney disease; lung disorders including pneumonia or fluid accumulation in the lungs; increased sensitivity of the skin to the sun; blood vessel inflammation; a skin disease characterized by peeling of the skin all over the body; cutaneous lupus erythematosus, which is identified by a rash that can appear on the face, neck, and scalp; allergic reactions; weakness and muscle spasms; heart rhythm disturbances; low blood pressure after changing body position; swelling of the salivary glands; high blood sugar levels; sugar in the urine; increased levels of certain blood fats; high uric acid levels in the blood, which can cause gout.
Very rare:Acute respiratory distress (signs include severe difficulty breathing, fever, weakness, and confusion).
Frequency “not known”(cannot be estimated from the available data): skin and lip cancer (non-melanoma skin cancer), decreased vision or eye pain due to increased pressure (possible signs of fluid accumulation in the vascular layer of the eye (choroidal effusion) or acute angle-closure glaucoma).
It is known that side effects associated with hydrochlorothiazide can increase with higher doses of hydrochlorothiazide.
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and on the blister after EXP. The expiry date refers to the last day of the month shown.
Do not store above 30 °C.
Store in the original packaging to protect from moisture.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of CoAprovel
Appearance and packaging of the product
The film-coated tablets of CoAprovel 300 mg/12.5 mg are peach, biconvex, oval-shaped, with a heart-shaped indentation on one side and the number 2876 engraved on the other.
CoAprovel 300 mg/12.5 mg film-coated tablets are available in blister packs of 14, 28, 30, 56, 84, 90 or 98 film-coated tablets. They are also available in unit dose blister packs of 56 x 1 film-coated tablet for hospital use.
Not all pack sizes may be marketed.
Marketing authorisation holder
Sanofi Winthrop Industrie
82 avenue Raspail
94250 Gentilly
France
Manufacturer
SANOFI WINTHROP INDUSTRIE1, rue de la ViergeAmbarès & LagraveF‑33565 Carbon Blanc Cedex - France
SANOFI WINTHROP INDUSTRIE30-36 Avenue Gustave Eiffel37100 Tours - France
SANOFI-AVENTIS, S.A.
Ctra. C-35 (La Batlloria-Hostalric), km. 63.09
17404 Riells i Viabrea (Girona)
Spain
You can request more information about this medicine from the local representative of the marketing authorisation holder:
België/Belgique/Belgien Sanofi Belgium Tel: +32 (0)2 710 54 00 | Luxembourg/Luxemburg Sanofi Belgium Tel: +32 (0)2 710 54 00 (Belgique/Belgien) |
Magyarország sanofi-aventis zrt., Magyarország Tel.: +36 1 505 0050 | |
Ceská republika Sanofi, s.r.o. Tel: +420 233 086 111 | Malta Sanofi S.r.l. Tel: +39 02 39394275 |
Danmark Sanofi A/S Tlf: +45 45 16 70 00 | Nederland Sanofi B.V. Tel: +31 20 245 4000 |
Deutschland Sanofi-Aventis Deutschland GmbH Tel: 0800 52 52 010 Tel. from abroad: +49 69 305 21 131 | Norge sanofi-aventis Norge AS Tlf: +47 67 10 71 00 |
Eesti Swixx Biopharma OÜ Tel: +372 640 10 30 | Österreich sanofi-aventis GmbH Tel: +43 1 80 185 – 0 |
Ελλάδα Sanofi-Aventis Μονοπρ?σωπη AEBE Τηλ: +30 210 900 16 00 | Polska Sanofi Sp. z o.o. Tel.: +48 22 280 00 00 |
España sanofi-aventis, S.A. Tel: +34 93 485 94 00 | Portugal Sanofi - Produtos Farmacêuticos, Lda Tel: +351 21 35 89 400 |
France Sanofi Winthrop Industrie Tél: 0 800 222 555 Appel depuis l’étranger: +33 1 57 63 23 23 Hrvatska Swixx Biopharma d.o.o. Tel:+385 1 2078 500 | România Sanofi Romania SRL Tel: +40 (0) 21 317 31 36 |
Ireland sanofi-aventis Ireland Ltd. T/A SANOFI Tel: +353 (0) 1 403 56 00 | Slovenija Swixx Biopharma d.o.o. Tel: +386 1 235 51 00 |
Ísland Vistor hf. Sími: +354 535 7000 | Slovenská republika Swixx Biopharma s.r.o. Tel: +421 2 208 33 600 |
Italia Sanofi S.r.l. Tel: 800.536389 | Suomi/Finland Sanofi Oy Puh/Tel: +358 (0) 201 200 300 |
Κ?προς C.A. Papaellinas Ltd. Τηλ: +357 22 741741 | Sverige Sanofi AB Tel: +46 (0)8 634 50 00 |
Latvija Swixx Biopharma SIA Tel: +371 6616 47 50 | United Kingdom (Northern Ireland) sanofi-aventis Ireland Ltd. T/A SANOFI Tel: +44 (0) 800 035 2525 |
Lietuva Swixx Biopharma UAB Tel: +370 5 236 91 40 |
Date of last revision of this leaflet:
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.
The average price of COAPROVEL 300 mg/12.5 mg FILM-COATED TABLETS in October, 2025 is around 19.29 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.